GlobeNewswire: Anchiano Therapeutics Contains the last 10 of 38 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T13:18:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2021/03/15/2193227/0/en/Anchiano-Announces-Shareholder-Approval-of-the-Merger-with-Chemomab-and-Prices-45-5M-Private-Financing.html?f=22&fvtc=4&fvtv=45288Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing2021-03-15T21:54:21Z<![CDATA[Anchiano shareholders approve all resolutions at shareholder meeting]]>https://www.globenewswire.com/news-release/2020/12/15/2145458/0/en/Anchiano-Therapeutics-and-Chemomab-Announce-Entry-Into-Definitive-Merger-Agreement.html?f=22&fvtc=4&fvtv=45288Anchiano Therapeutics and Chemomab Announce Entry Into Definitive Merger Agreement2020-12-15T14:00:00Z<![CDATA[Merger brings lead compound CM-101, a first in class anti-CCL24 antibody into advanced clinical development for fibrosis-related diseases with significant unmet medical need]]>https://www.globenewswire.com/news-release/2020/05/26/2038586/0/en/Anchiano-Appoints-Stan-Polovets-as-Chairman-of-the-Board.html?f=22&fvtc=4&fvtv=45288Anchiano Appoints Stan Polovets as Chairman of the Board2020-05-26T12:00:00Z<![CDATA[CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced that Mr. Stan Polovets has been elected chairman of its board of directors.]]>https://www.globenewswire.com/news-release/2020/05/11/2031382/0/en/Anchiano-Therapeutics-Reports-First-Quarter-2020-Financial-Results.html?f=22&fvtc=4&fvtv=45288Anchiano Therapeutics Reports First Quarter 2020 Financial Results2020-05-11T20:01:00Z<![CDATA[CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a preclinical biopharmaceutical company dedicated to the discovery and development of new cancer therapies designed to target the products of mutated genes that are drivers of human malignancies, today reported financial results for its first quarter ended March 31, 2020.]]>https://www.globenewswire.com/news-release/2020/05/05/2028022/0/en/Anchiano-Appoints-Steve-DiPalma-as-Chief-Financial-Officer.html?f=22&fvtc=4&fvtv=45288Anchiano Appoints Steve DiPalma as Chief Financial Officer2020-05-05T22:13:31Z<![CDATA[CAMBRIDGE, Mass., May 05, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has appointed Mr. Steve DiPalma as its Chief Financial Officer. Mr. DiPalma has served as a Senior Financial Advisor to Anchiano by agreement with Danforth Advisors since 2018; he will succeed Jonathan Burgin, who is leaving the Company as part of the planned closure of the Company’s Israel offices and facilities. Mr. Burgin will remain in the position of Chief Operating Officer until the final closure of the Israeli offices and facilities on May 31, 2020. The Company also entered into a consulting agreement with Mr. Burgin, pursuant to which Mr. Burgin agreed to support the financial, accounting and treasury functions of the Company following his departure.]]>https://www.globenewswire.com/news-release/2020/04/17/2018184/0/en/Anchiano-to-Hold-Virtual-Annual-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=45288Anchiano to Hold Virtual Annual Meeting of Shareholders2020-04-17T20:01:00Z<![CDATA[CAMBRIDGE, Mass., April 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) today announced it has elected to hold its 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) as a virtual meeting due to the ongoing public health concerns related to the coronavirus (COVID-19) pandemic. The Annual Meeting will still be held on April 23, 2020 at 11:00 a.m. (Eastern Daylight Time).]]>https://www.globenewswire.com/news-release/2020/03/18/2002560/0/en/Anchiano-Therapeutics-Reports-Year-End-2019-Financial-Results.html?f=22&fvtc=4&fvtv=45288Anchiano Therapeutics Reports Year-End 2019 Financial Results2020-03-18T12:00:00Z<![CDATA[CAMBRIDGE, Mass., March 18, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today reported financial results for the year ended December 31, 2019.]]>https://www.globenewswire.com/news-release/2020/01/17/1972169/0/en/Anchiano-Therapeutics-Announces-Record-Date-for-2020-Annual-General-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=45288Anchiano Therapeutics Announces Record Date for 2020 Annual General Meeting of Shareholders2020-01-17T21:05:00Z<![CDATA[CAMBRIDGE, Mass., Jan. 17, 2020 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (the “Company”) announced today that its board of directors approved the record date for the Company’s 2020 Annual General Meeting of Shareholders (the “Annual Meeting”) to be held on or about March 23, 2020. The matters raised by Access Industries Holdings LLC and Clal Biotechnology Industries Ltd. will be addressed at the Annual Meeting. Holders of the Company’s ordinary shares and holders of the Company’s American Depositary Shares at the close of business on February 17, 2020, the record date, will be entitled to receive notice of, and to vote at, the Annual Meeting.]]>https://www.globenewswire.com/news-release/2019/11/15/1948007/0/en/Anchiano-Therapeutics-Reports-Third-Quarter-2019-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=45288Anchiano Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update2019-11-15T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”), a biopharmaceutical company focused on discovery and development of novel therapies to treat cancer, today reported financial results for its third quarter and nine months ended September 30, 2019.]]>https://www.globenewswire.com/news-release/2019/11/15/1948010/0/en/Anchiano-Discontinues-Phase-2-Codex-Study-Evaluating-Inodiftagene-Vixteplasmid-in-Patients-with-Non-Muscle-Invasive-Bladder-Cancer-NMIBC-Company-Focuses-on-Advancing-Pan-RAS-Inhibi.html?f=22&fvtc=4&fvtv=45288Anchiano Discontinues Phase 2 Codex Study Evaluating Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC); Company Focuses on Advancing Pan-RAS Inhibitor Program2019-11-15T13:30:00Z<![CDATA[CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano” or the “Company”), a biopharmaceutical company focused on discovery and development of targeted therapies to treat cancer, today announced the discontinuation of its Phase 2 Codex study evaluating the gene therapy inodiftagene vixteplasmid in patients with BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC). After a thorough analysis of the data, Anchiano determined that there is a low probability of surpassing the pre-defined futility threshold at the planned interim analysis, which required 10 complete responses in 35 patients. The data also indicate a low probability of achieving an efficacy profile that in the company’s estimation would be necessary to support regulatory approval.]]>